Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › JNJ-73763989

JNJ-73763989

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of JNJ-73763989

7 trials tracked of JNJ-73763989.

7Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 7
  1. Phase 2 A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus Completed
  2. Phase 2 An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants Completed
  3. Phase 2 A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection Completed
  4. Phase 2 A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection Completed
  5. Phase 2 A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection Completed
  6. Phase 2 A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection Completed
Show 1 more trials
  1. Phase 2 A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 2 trial of JNJ-73763989-based regimen shows no HBsAg seroclearance at primary endpoint in HBeAg-positive CHB
Gastroenterology Phase II
Phase 2 trial of JNJ-73763989-based regimen shows no HBsAg seroclearance at primary endpoint in HBeAg-positive CHB New combo lowers hepatitis B virus levels
A phase 2 trial in 54 treatment-naïve, HBeAg-positive chronic hepatitis B patients tested a regimen of JNJ-73763989 ± bersacapavir with nucl…
A new drug combination successfully lowered virus levels in many patients, though clearing the virus completely happened in only about one o…
Apr 12, 2026